Premium
Serum alpha fetoprotein concentration and tumor growth dissociation in a patient with ovarian teratocarcinoma
Author(s) -
Esterhay Robert J.,
Shapiro Howard M.,
Sutherland John C.,
McIntire K. Robert,
Wiernik Peter H.
Publication year - 1973
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197304)31:4<835::aid-cncr2820310411>3.0.co;2-l
Subject(s) - alpha fetoprotein , teratocarcinoma , medicine , radioimmunoassay , teratoma , alpha (finance) , endocrinology , ovarian cancer , malignant disease , pathology , cancer , surgery , chemistry , biochemistry , construct validity , cellular differentiation , hepatocellular carcinoma , patient satisfaction , gene
Abstract A 17‐year‐old girl with a malignant ovarian teratoma had an elevated concentration of alpha fetoprotein detected in her serum by an electroimmunodiffusion technique when first seen. Surgery and chemotherapy resulted in regression of all measurable disease and a decrease in alpha fetoprotein level which was not detectable by the electroimmunodiffusion technique. A radioimmunoassay technique demonstrated the decrease in serum concentration of alpha fetoprotein and continuing decrease even though there was subsequent recurrence of tumor. Thus, the disease activity in malignant ovarian teratoma may not always correlate well with serum alpha fetoprotein concentration.